We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CTI BioPharma Corporation | NASDAQ:CTIC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.09 | 10.01 | 8.64 | 0 | 01:00:00 |
From May 2019 to May 2024
SEATTLE, Nov. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the Jefferies 2017 London Healthcare Conference Wednesday, November 15, 2017 at 12:20 p.m. ET / 5:20 p.m. GMT in London.
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.
CTI BioPharma Contacts:
Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com
View original content with multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jefferies-2017-london-healthcare-conference-300551414.html
SOURCE CTI BioPharma Corp.
Copyright 2017 PR Newswire
1 Year CTI BioPharma Chart |
1 Month CTI BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
